Key facts
- This page summarizes BIOTECH TARGET N V's Form 4 filing for Radius Health, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Aug 2022, 12:05.
BIOTECH TARGET N V - 15 Aug 2022 Form 4 Insider Report for Radius Health, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 15 Aug 2022
- Net transaction value
- -$87,335,380
- SEC form
- 4
- Accepted by SEC
- 30 Aug 2022, 12:05:50 UTC
- Prior SEC filing
- 20 May 2022
- Next SEC filing
- 21 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/Ivo Betschart
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
BIOTECH TARGET N V filed Form 4 for Radius Health, Inc. on 30 Aug 2022.
Change
- Previous filing in this sequence was filed on 20 May 2022.
- Current net transaction value: -$87,335,380.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RDUS
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- $87,335,380
- Shares
- -8,733,538
- Change %
- -100%
- Price
- $10.00
- Shares after
- 0
- Date
- 11 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
BIOTECH TARGET N V is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer.
SEC remarks
Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Radius Health, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.